title: Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia.
abstract: To explore the factors for achieving early molecular responses (EMR; BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months) by imatinib (IM), baseline characteristics including individual BCR-ABL1 transcript level, dose intensity, and IM trough level on day 29 were analyzed in 286 chronic phase chronic myeloid leukemia patients. Distinct predictive factors for achieving EMR at 3 months and 6 months were noted. Blast count at diagnosis and IM trough level on day 29 were significantly associated with an achievement of 3-month EMR. Early decline of BCR-ABL1 transcript, low Sokal risk, and mean daily dose (≥350mg/day) by 6 months were associated with an achievement of 6-month EMR. Understanding the predictive factors for EMR may provide additional information to guide clinical decisions on the changing therapies at each landmark.
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea; Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors: Sung-Eun
authors: SE
authors: Lee
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Soo Young
authors: SY
authors: Choi
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Yun Jeong
authors: YJ
authors: Oh
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Soo-Hyun
authors: SH
authors: Kim
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Hye-Young
authors: HY
authors: Song
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Hea-Lyun
authors: HL
authors: Yoo
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Mi-Young
authors: MY
authors: Lee
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Moon-Jung
authors: MJ
authors: Chae
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Ki-Hoon
authors: KH
authors: Kang
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Hee-Jeong
authors: HJ
authors: Hwang
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Eun-Jung
authors: EJ
authors: Jang
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea; Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea. Electronic address: dwkim@catholic.ac.kr.
authors: Dong-Wook
authors: DW
authors: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D013997:Time Factors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: Chronic myeloid leukemia; Early molecular response; Imatinib